APA (7th ed.) Citation

Long, G., Gutzmer, R., Haydon, A., Couselo, E. M., Lebbé, C., Carlino, M., . . . Rutkowski, P. A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127). Elsevier.

Chicago Style (17th ed.) Citation

Long, G.V, et al. A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics Profile of Subcutaneous Vs Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127). Elsevier.

MLA (9th ed.) Citation

Long, G.V, et al. A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics Profile of Subcutaneous Vs Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127). Elsevier.